Edition:
India

Biomerieux SA (BIOX.PA)

BIOX.PA on Paris Stock Exchange

70.60EUR
23 May 2018
Change (% chg)

€-0.20 (-0.28%)
Prev Close
€70.80
Open
€70.60
Day's High
€71.00
Day's Low
€69.50
Volume
92,756
Avg. Vol
131,526
52-wk High
€79.80
52-wk Low
€59.00

Latest Key Developments (Source: Significant Developments)

Biomerieux Q1 Sales Up 3.4 Percent 587 Million Euros
Thursday, 19 Apr 2018 

April 19 (Reuters) - BIOMERIEUX SA ::Q1 SALES EUR 587 MILLION UP 3.4 PERCENT YOY.NET DEBT AMOUNTED TO EUR 84 MILLION AT MARCH 31, 2018, VERSUS EUR 156 MILLION AT DECEMBER 31, 2017.SALES OF CLINICAL APPLICATIONS ROSE BY 13.5% YEAR-ON-YEAR TO EUR 486 MILLION FOR Q1.  Full Article

Biomerieux Acquires Astute Medical Inc. For About $90 Mln In Cash
Wednesday, 4 Apr 2018 

April 4 (Reuters) - BIOMERIEUX SA ::ANNOUNCED ON WEDNESDAY, ACQUISITION OF ASTUTE MEDICAL INC FOR ABOUT $90 MLN IN CASH.ESTIMATED OPERATING EXPENSES RELATED TO ASTUTE FOR REMAINING 9 MONTHS OF YR COULD DRIVE AN IMPACT OF -60 BPS ON 2018 CONTRIBUTIVE OPERATING INCOME .  Full Article

Biomerieux FY ‍Sales Rise 10.2 Pct To EUR 2,288 Million
Tuesday, 23 Jan 2018 

Jan 23 (Reuters) - BIOMERIEUX SA ::‍SALES MOMENTUM IN 2017 WITH 10.2% GROWTH IN SALES TO EUR 2,288 MILLION IN SALES​.NET DEBT AMOUNTED TO EUR 156 MILLION AT DECEMBER 31, 2017, VERSUS EUR 275 MILLION AT DECEMBER 31, 2016..Q4 2017 SALES FOR BIOMÉRIEUX ROSE 8.9% ON Q4 2016​.EXPECTS CONTRIBUTIVE OPERATING INCOME BEFORE NON-RECURRING ITEMS TO BE IN LINE WITH ITS PREVIOUS TARGET.CHANGE IN FEDERAL INCOME TAX RATE WILL IMPACT FISCAL YEAR 2017 WITH A NON-RECURRING AND NON-CASH BENEFIT OF AROUND EUR 30 MLN.BIOMÉRIEUX ESTIMATES EFFECTIVE TAX RATE IN 2018 AT BETWEEN 24% AND 26%.  Full Article

Biomerieux Q3 sales up at ‍​1.67 billion euros
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - BIOMERIEUX SA ::Q3 SALES EUR ‍​1.67 BILLION VERSUS EUR 1.51 BILLION YEAR AGO.  Full Article

Biomerieux introduces Evisight Compact
Thursday, 6 Oct 2016 

Biomerieux SA :Biomerieux introduces Evisight Compact, a new automated diagnostic solution for microbial detection in pharmaceutical production.  Full Article

Biomerieux 2016 guidance revised to top of range
Wednesday, 31 Aug 2016 

Biomerieux SA : H1 net income of consolidated companies 86 million euros ($95.9 million) versus 59 million euros a year ago . 2016 financial targets revised . 2016 organic sales growth could end year at or above higher end of previously targeted 6.0 pct to 8.0 pct range . FY contributive operating income before non-recurring items expected to come in at around the top of the initially targeted 265 million euros to 290 million euros range . Consolidated net debt amounted to 265 million euros at June 30, 2016 versus 219 million euros at December 31, 2015 .H1 operating income 146 million euros versus 103 million euros year ago.  Full Article

Biomerieux H1 sales up 10.9 pct, at constant exchange rates and scope of consolidation
Monday, 18 Jul 2016 

Biomerieux SA : Strong growth in sales, up 10.9 pct, at constant exchange rates and scope of consolidation in first half of 2016 .H1 sales reached 1,001 million euros ($1.11 billion).  Full Article

Biomerieux reports Q2 growth in sales of 10.9 pct
Monday, 18 Jul 2016 

Biomerieux SA : Q2 strong growth in sales, up 10.9 pct, at constant exchange rates and scope of consolidation in first half of 2016 .Q2 sales reached 1,001 million euros ($1.11 billion).  Full Article

BRIEF-Biomerieux Q1 Sales Up 3.4 Percent 587 Million Euros

* NET DEBT AMOUNTED TO EUR 84 MILLION AT MARCH 31, 2018, VERSUS EUR 156 MILLION AT DECEMBER 31, 2017